ATROPINE

First marketed in 1921

Details

Stereochemistry	EPIMERIC
Molecular Formula	C17H23NO3
Molecular Weight	289.3701
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 3
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CN1[C@@]2([H])CC[C@]1([H])C[C@@]([H])(C2)OC(=O)C([H])(CO)c3ccccc3

InChI

InChIKey=RKUNBYITZUJHSG-SPUOUPEWSA-N

InChI=1S/C17H23NO3/c1-18-13-7-8-14(18)10-15(9-13)21-17(20)16(11-19)12-5-3-2-4-6-12/h2-6,13-16,19H,7-11H2,1H3/t13-,14+,15+,16?

HIDE SMILES / InChI

Molecular Formula	C17H23NO3
Molecular Weight	289.3701
Charge	0
Count

Stereochemistry	EPIMERIC
Additional Stereochemistry	No
Defined Stereocenters	2 / 3
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021146s015lbl.pdf
Curator's Comment:: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/mesh/68001285 | http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206289s000lbl.pdf

Atropine inhibits the muscarinic actions of acetylcholine on structures innervated by postganglionic cholinergic nerves, and on smooth muscles which respond to endogenous acetylcholine but are not so innervated. As with other antimuscarinic agents, the major action of atropine is a competitive or surmountable antagonism which can be overcome by increasing the concentration of acetylcholine at receptor sites of the effector organ (e.g., by using anticholinesterase agents which inhibit the enzymatic destruction of acetylcholine). The receptors antagonized by atropine are the peripheral structures that are stimulated or inhibited by muscarine (i.e., exocrine glands and smooth and cardiac muscle). Responses to postganglionic cholinergic nerve stimulation also may be inhibited by atropine but this occurs less readily than with responses to injected (exogenous) choline esters. Atropine is relatively selective for muscarinic receptors. Its potency at nicotinic receptors is much lower, and actions at non-muscarinic receptors are generally undetectable clinically. Atropine does not distinguish among the M1, M2, and M3 subgroups of muscarinic receptors.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Muscarinic acetylcholine receptor M1 78 Target ID: CHEMBL216 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206289s000lbl.pdf	Antagonist 1131	9.34 null [pKi]
Muscarinic acetylcholine receptor M2 49 Target ID: CHEMBL211 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206289s000lbl.pdf	Antagonist 1131	8.95 null [pKi]
Muscarinic acetylcholine receptor M3 73 Target ID: CHEMBL245 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206289s000lbl.pdf	Antagonist 1131	9.15 null [pKi]

Conditions

Condition	Modality	Highest Phase	Product
Bradyasystolic cardiac arrest 4 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021146s015lbl.pdf	Primary	Approved 4033	Atropine sulfate Approved Use Atropine sulfate is indicated for temporary blockade of severe or life threatening muscarinic effects, e.g., as an antisialagogue, an antivagal agent, an antidote for organophosphorus or muscarinic mushroom poisoning, and to treat bradyasystolic cardiac arrest. Launch Date 9.9455042E11
Organophosphorus poisoning 4 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021146s015lbl.pdf	Primary	Approved 4033	Atropine sulfate Approved Use Atropine sulfate is indicated for temporary blockade of severe or life threatening muscarinic effects, e.g., as an antisialagogue, an antivagal agent, an antidote for organophosphorus or muscarinic mushroom poisoning, and to treat bradyasystolic cardiac arrest. Launch Date 9.9455042E11
Increased salivary flow 4 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021146s015lbl.pdf	Primary	Approved 4033	Atropine sulfate Approved Use Atropine sulfate is indicated for temporary blockade of severe or life threatening muscarinic effects, e.g., as an antisialagogue, an antivagal agent, an antidote for organophosphorus or muscarinic mushroom poisoning, and to treat bradyasystolic cardiac arrest. Launch Date 9.9455042E11
Vagus nerve activation 4 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021146s015lbl.pdf	Primary	Approved 4033	Atropine sulfate Approved Use Atropine sulfate is indicated for temporary blockade of severe or life threatening muscarinic effects, e.g., as an antisialagogue, an antivagal agent, an antidote for organophosphorus or muscarinic mushroom poisoning, and to treat bradyasystolic cardiac arrest. Launch Date 9.9455042E11
Muscarinic mushroom poisoning 4 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021146s015lbl.pdf	Primary	Approved 4033	Atropine sulfate Approved Use Atropine sulfate is indicated for temporary blockade of severe or life threatening muscarinic effects, e.g., as an antisialagogue, an antivagal agent, an antidote for organophosphorus or muscarinic mushroom poisoning, and to treat bradyasystolic cardiac arrest. Launch Date 9.9455042E11

C_max

Value	Dose	Analyte	Population
860 pg/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/3046815	0.4 μg single, ocular dose: 0.4 μg route of administration: Ocular experiment type: SINGLE co-administered:	ATROPINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
11.7 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/3740650	1.67 mg single, intramuscular dose: 1.67 mg route of administration: Intramuscular experiment type: SINGLE co-administered:	ATROPINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
9.6 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/212319s000lbl.pdf	1.67 mg single, intramuscular dose: 1.67 mg route of administration: Intramuscular experiment type: SINGLE co-administered:	ATROPINE plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
43245 pg × min/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/3046815	0.4 μg single, ocular dose: 0.4 μg route of administration: Ocular experiment type: SINGLE co-administered:		ATROPINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
47.6 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/3740650	1.67 mg single, intramuscular dose: 1.67 mg route of administration: Intramuscular experiment type: SINGLE co-administered:		ATROPINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
4.1 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/3740650	1.67 mg single, intramuscular dose: 1.67 mg route of administration: Intramuscular experiment type: SINGLE co-administered:		ATROPINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
82% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/212319s000lbl.pdf	1.67 mg single, intramuscular dose: 1.67 mg route of administration: Intramuscular experiment type: SINGLE co-administered:		ATROPINE plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
0.1 mg/kg single, intravenous Dose: 0.1 mg/kg Route: intravenous Route: single Dose: 0.1 mg/kg Sources: https://pubmed.ncbi.nlm.nih.gov/29316984	unhealthy, 10 years n = 1 Health Status: unhealthy Age Group: 10 years Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/29316984	Disc. AE: Kounis syndrome, Chest discomfort... AEs leading to discontinuation/dose reduction: Kounis syndrome (1 patient) Chest discomfort (1 patient) Nausea (1 patient) Vomiting (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/29316984
0.5 % 1 times / day multiple, ophthalmic Highest studied dose Dose: 0.5 %, 1 times / day Route: ophthalmic Route: multiple Dose: 0.5 %, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/27101751	unhealthy, 10.3 years (range: 2.7–16.8 years) n = 77 Health Status: unhealthy Condition: progressive myopia Age Group: 10.3 years (range: 2.7–16.8 years) Sex: M+F Population Size: 77 Sources: https://pubmed.ncbi.nlm.nih.gov/27101751	Other AEs: Photophobia, Reading disorder... Other AEs: Photophobia (70%) Reading disorder (25.9%) Headache (21.7%) Hot flushes (3.3%) Conjunctivitis (1.7%) Blepharitis (1.7%) Sources: https://pubmed.ncbi.nlm.nih.gov/27101751
1 mg single, sublingual Overdose Dose: 1 mg Route: sublingual Route: single Dose: 1 mg Sources: https://pubmed.ncbi.nlm.nih.gov/33521988	unhealthy n = 1 Health Status: unhealthy Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/33521988	Other AEs: Adverse event... Other AEs: Adverse event (severe) Sources: https://pubmed.ncbi.nlm.nih.gov/33521988

AEs

AE	Significance	Dose	Population
Chest discomfort	1 patient Disc. AE	0.1 mg/kg single, intravenous Dose: 0.1 mg/kg Route: intravenous Route: single Dose: 0.1 mg/kg Sources: https://pubmed.ncbi.nlm.nih.gov/29316984	unhealthy, 10 years n = 1 Health Status: unhealthy Age Group: 10 years Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/29316984
Kounis syndrome	1 patient Disc. AE	0.1 mg/kg single, intravenous Dose: 0.1 mg/kg Route: intravenous Route: single Dose: 0.1 mg/kg Sources: https://pubmed.ncbi.nlm.nih.gov/29316984	unhealthy, 10 years n = 1 Health Status: unhealthy Age Group: 10 years Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/29316984
Nausea	1 patient Disc. AE	0.1 mg/kg single, intravenous Dose: 0.1 mg/kg Route: intravenous Route: single Dose: 0.1 mg/kg Sources: https://pubmed.ncbi.nlm.nih.gov/29316984	unhealthy, 10 years n = 1 Health Status: unhealthy Age Group: 10 years Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/29316984
Vomiting	1 patient Disc. AE	0.1 mg/kg single, intravenous Dose: 0.1 mg/kg Route: intravenous Route: single Dose: 0.1 mg/kg Sources: https://pubmed.ncbi.nlm.nih.gov/29316984	unhealthy, 10 years n = 1 Health Status: unhealthy Age Group: 10 years Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/29316984
Blepharitis	1.7%	0.5 % 1 times / day multiple, ophthalmic Highest studied dose Dose: 0.5 %, 1 times / day Route: ophthalmic Route: multiple Dose: 0.5 %, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/27101751	unhealthy, 10.3 years (range: 2.7–16.8 years) n = 77 Health Status: unhealthy Condition: progressive myopia Age Group: 10.3 years (range: 2.7–16.8 years) Sex: M+F Population Size: 77 Sources: https://pubmed.ncbi.nlm.nih.gov/27101751
Conjunctivitis	1.7%	0.5 % 1 times / day multiple, ophthalmic Highest studied dose Dose: 0.5 %, 1 times / day Route: ophthalmic Route: multiple Dose: 0.5 %, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/27101751	unhealthy, 10.3 years (range: 2.7–16.8 years) n = 77 Health Status: unhealthy Condition: progressive myopia Age Group: 10.3 years (range: 2.7–16.8 years) Sex: M+F Population Size: 77 Sources: https://pubmed.ncbi.nlm.nih.gov/27101751
Headache	21.7%	0.5 % 1 times / day multiple, ophthalmic Highest studied dose Dose: 0.5 %, 1 times / day Route: ophthalmic Route: multiple Dose: 0.5 %, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/27101751	unhealthy, 10.3 years (range: 2.7–16.8 years) n = 77 Health Status: unhealthy Condition: progressive myopia Age Group: 10.3 years (range: 2.7–16.8 years) Sex: M+F Population Size: 77 Sources: https://pubmed.ncbi.nlm.nih.gov/27101751
Reading disorder	25.9%	0.5 % 1 times / day multiple, ophthalmic Highest studied dose Dose: 0.5 %, 1 times / day Route: ophthalmic Route: multiple Dose: 0.5 %, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/27101751	unhealthy, 10.3 years (range: 2.7–16.8 years) n = 77 Health Status: unhealthy Condition: progressive myopia Age Group: 10.3 years (range: 2.7–16.8 years) Sex: M+F Population Size: 77 Sources: https://pubmed.ncbi.nlm.nih.gov/27101751
Hot flushes	3.3%	0.5 % 1 times / day multiple, ophthalmic Highest studied dose Dose: 0.5 %, 1 times / day Route: ophthalmic Route: multiple Dose: 0.5 %, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/27101751	unhealthy, 10.3 years (range: 2.7–16.8 years) n = 77 Health Status: unhealthy Condition: progressive myopia Age Group: 10.3 years (range: 2.7–16.8 years) Sex: M+F Population Size: 77 Sources: https://pubmed.ncbi.nlm.nih.gov/27101751
Photophobia	70%	0.5 % 1 times / day multiple, ophthalmic Highest studied dose Dose: 0.5 %, 1 times / day Route: ophthalmic Route: multiple Dose: 0.5 %, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/27101751	unhealthy, 10.3 years (range: 2.7–16.8 years) n = 77 Health Status: unhealthy Condition: progressive myopia Age Group: 10.3 years (range: 2.7–16.8 years) Sex: M+F Population Size: 77 Sources: https://pubmed.ncbi.nlm.nih.gov/27101751
Adverse event	severe	1 mg single, sublingual Overdose Dose: 1 mg Route: sublingual Route: single Dose: 1 mg Sources: https://pubmed.ncbi.nlm.nih.gov/33521988	unhealthy n = 1 Health Status: unhealthy Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/33521988

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
OCT1 254 OCT2 297 OCT3 82

Drug as perpetrator

Target	Modality	Activity
OCT1 266	inhibitor 1612 Sources: http://www.ncbi.nlm.nih.gov/pubmed/16263091	yes [IC50 1.2 uM]
OCT2 298	inhibitor 1612 Sources: http://www.ncbi.nlm.nih.gov/pubmed/16263091	yes [IC50 39 uM]
OCT3 82	inhibitor 1612 Sources: http://www.ncbi.nlm.nih.gov/pubmed/16263091	yes [IC50 466 uM]

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:16684	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:16684
ChemicalBook	CB2163178	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB2163178
MolPort	MolPort-001-742-593	https://www.molport.com/shop/molecule-link/MolPort-001-742-593
eMolecules	478873	https://www.emolecules.com/cgi-bin/more?vid=478873

PubMed

Title	Date	PubMed
Selective blocking effects of tropisetron and atropine on recombinant glycine receptors.	1999 Aug	10428078
Attenuation of focal adhesion kinase signaling following depletion of agonist-sensitive pools of phosphatidylinositol 4,5-bisphosphate.	1999 Nov	10537051
Focal microinjection of carbachol into the periaqueductal gray induces seizures in the forebrain of the rat.	2000 Dec	11074189
Acute cardiac rupture during dobutamine-atropine echocardiography stress test.	2000 Feb	10668020
Influence of nitric oxide donors and of the alpha(2)-agonist UK-14,304 on acetylcholine release in the pig gastric fundus.	2001	11114406
Endothelin receptors in human and guinea-pig gallbladder muscle.	2001 Apr 20	11231044
Localisation and neural control of the release of calcitonin gene-related peptide (CGRP) from the isolated perfused porcine ileum.	2001 Apr 20	11231043
Accelerated dobutamine stress testing: safety and feasibility in patients with known or suspected coronary artery disease.	2001 Feb	11214744
On the mechanisms of cholinergic control of the sinoatrial node discharge.	2001 Feb	11210000
Sublingual hyoscyamine sulfate in combination with ketorolac tromethamine for ureteral colic: a randomized, double-blind, controlled trial.	2001 Feb	11174230
Cardiac sympathetic overactivity and decreased baroreflex sensitivity in L-NAME hypertensive rats.	2001 Feb	11158985
Muscarinic receptor subtypes and calcium signaling in Fischer rat thyroid cells.	2001 Feb 1	11172738
Characterisation of the prejunctional inhibitory muscarinic receptor on cholinergic nerves in the rat urinary bladder.	2001 Feb 16	11226391
Stimulation of M3 muscarinic receptors induces phosphorylation of the Cdc42 effector activated Cdc42Hs-associated kinase-1 via a Fyn tyrosine kinase signaling pathway.	2001 Feb 23	11087735
Increase of peak expiratory flow by atropine is dependent on circadian rhythm.	2001 Jan	11212055
High concentration sevoflurane induction of anesthesia accelerates onset of vecuronium neuromuscular blockade.	2001 Jan	11212046
Tachykinins contribute to nerve-mediated contractions in the human esophagus.	2001 Jan	11208712
Influence of patient posture on oxygen saturation during fibre-optic bronchoscopy.	2001 Jan	11207018
Hypotensive infarction of the spinal cord in a rhesus macaque (Macaca mulatta).	2001 Jan	11199156
Spectral analysis of circadian rhythms in heart rate variability of dogs.	2001 Jan	11197557
Effects of VIP and NO on the motor activity of vascularly perfused rat proximal colon.	2001 Jan	11179602
Neural mechanisms underlying migrating motor complex formation in mouse isolated colon.	2001 Jan	11159701
Evidence for cocaine and methylecgonidine stimulation of M(2) muscarinic receptors in cultured human embryonic lung cells.	2001 Jan	11159694
Characterization of a novel mechanism accounting for the adverse cholinergic effects of the anticancer drug irinotecan.	2001 Jan	11156563
Comparison of myocardial blood flow during dobutamine-atropine infusion with that after dipyridamole administration in normal men.	2001 Jan	11153727
Reversal of Haemorrhagic Shock in Rats by Tetrahydroaminoacridine.	2001 Jan	11150921
Non-synaptic transformation of gustatory receptor potential by stimulation of the parasympathetic fiber of the frog glossopharyngeal nerve.	2001 Jan	11124218
Xerostomia, xerophthalmia, and plasmacytic infiltrates of the salivary glands (Sjögren's-like syndrome) in a cat.	2001 Jan 1	11149716
Effects of preemptive atropine administration on incidence of medetomidine-induced bradycardia in dogs.	2001 Jan 1	11149715
Post-ictal analgesia: involvement of opioid, serotoninergic and cholinergic mechanisms.	2001 Jan 12	11150491
Changes in sensitivity of cholinoceptors and adrenoceptors during transhemispheric cortical reorganisation in rat SmI.	2001 Jan 12	11150484
Determination of scopolamine in human serum and microdialysis samples by liquid chromatography-tandem mass spectrometry.	2001 Jan 5	11204211
Activation of the parasympathetic nervous system is necessary for normal meal-induced insulin secretion in rhesus macaques.	2001 Mar	11238517
From 'captive' agonism to insurmountable antagonism: demonstrating the power of analytical pharmacology.	2001 Mar	11236130
Pharmacological characterization of locomotor sensitization induced by chronic phencyclidine administration.	2001 Mar	11181923
Low-affinity M(2) receptor binding state mediates mouse atrial bradycardia: comparative effects of carbamylcholine and the M(1) receptor agonists sabcomeline and xanomeline.	2001 Mar	11181912
Respective roles of carbamylcholine and cyclic adenosine monophosphate in their synergistic regulation of cell cycle in thyroid primary cultures.	2001 Mar	11181542
Orally administered atropine enhances motor cortex excitability: a transcranial magnetic stimulation study in human subjects.	2001 Mar 16	11226633
5-Hydroxytryptamine and atropine inhibit nicotinic receptors in submucosal neurons.	2001 Mar 2	11239911
The role of nitric oxide on the relaxations of rabbit corpus cavernosum induced by Androctonus australis and Buthotus judaicus scorpion venoms.	2001 May	11072041

Patents

Sample Use Guides

In Vivo Use Guide

Atropine as an antisialagogue or for antivagal effects: initial single dose of 0.5 mg to 1 mg; as an antidote for organophosporous or muscarinic mushroom poisoning: initial single dose of 2 mg to 3 mg, repeated every 20-30 minutes; for bradyasystolic cardiac arrest: 1 mg dose, repeated every 3-5 minutes if asystole persists; in patients with coronary artery disease: total dose should not exceed 0.03 mg/kg to 0.04 mg/kg.

Route of Administration: Other

In Vitro Use Guide

Atropine in doses -5.44 to -4.74 log mol/L totally inhibited the contraction induced by acetylcholine and carbachol in segmental pulmonary artery specimens taken from the patients undergoing thoracic surgery.

Substance Class	Chemical Created by `admin` on `Fri Jun 25 21:11:21 UTC 2021` Edited by `admin` on `Fri Jun 25 21:11:21 UTC 2021`
Record UNII	7C0697DR9I
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ATROPINE

Common Name

English

ATROPINE [USP]

Common Name

English

ATROPINE [VANDF]

Common Name

English

ATROPINE COMPONENT OF ATNAA

Common Name

English

(+/-)-HYOSCYAMINE

Common Name

English

BENZENEACETIC ACID, .ALPHA.-(HYDROXYMETHYL)-(3-ENDO)-8-METHYL-8-AZABICYCLO(3.2.1)OCT-3-YL ESTER

Common Name

English

ATROPEN

Brand Name

English

ATROPINE [WHO-DD]

Common Name

English

HOMATROPINE HYDROBROMIDE IMPURITY D [EP]

Common Name

English

ATROPINUM [HPUS]

Common Name

English

ATROPINE COMPONENT OF DUODOTE

Common Name

English

ATROPINE [ORANGE BOOK]

Common Name

English

DUODOTE COMPONENT ATROPINE

Common Name

English

ATROPINE ((+/-))

Common Name

English

(3-ENDO)-8-METHYL-8-AZABICYCLO(3.2.1)OCT-3-YL TROPATE

Common Name

English

ATROPINE [MI]

Common Name

English

ATROPINE, (+/-)-

Common Name

English

ATNAA COMPONENT ATROPINE

Common Name

English

ATROPINE [GREEN BOOK]

Common Name

English

ATROPINE [EP MONOGRAPH]

Common Name

English

ATROPINE [MART.]

Common Name

English

ATROPINUM

Common Name

English

BENZENEACETIC ACID, .ALPHA.-(HYDROXYMETHYL)-8-METHYL-8-AZABICYCLO(3.2.1)OCT-3-YL ESTER, ENDO-(+/-)-

Common Name

English

ATROPINE [EP]

Common Name

English

1.ALPHA.H,5.ALPHA.H-TROPAN-3.ALPHA.-OL (+/-)-TROPATE (ESTER)

Common Name

English

ATROPINE [USP-RS]

Common Name

English

DL-HYOSCYAMINE

Common Name

English

Classification Tree Code System Code

NDF-RT

N0000175370